Objective To analyze the changes of coagulation indexes in patients of non-valvular atrial fibrillation with different ABO blood types before and after treatment with the new oral anticoagulant dabigatran etexilate.

Methods A total of 100 patients with non-valvular atrial fibrillation were selected as research subjects, and they were divided into type O group (n=50) and non-type O group (n=50) according to blood types, and dabigatran etexilate capsules were given to both groups. The coagulation function indexes of the two groups after 3 months were compared.

Results Before treatment, there were significant differences in Von Willebrand factor (vWF) and protein C activities between two groups (P < 0.05). After treatment, the activities of vWF and protein C showed significant differences between two groups (P < 0.05). Before treatment, there was no significant difference in activated partial thromboplastin time (APTT) between the two groups (P > 0.05), but there was a significant difference in APTT between the two groups after treatment (P < 0.05). There were no significant between-group differences in plasma prothrombin time (PT), thrombin time (TT), international normalized ratio (INR) and coagulation factor Ⅷ before and after treatment (P > 0.05). There were significant differences in all coagulation related indexes between the two groups after treatment compared with treatment before (P < 0.05).

Conclusion Patients with type O blood are more likely to alert to occurrence of bleeding events when treated with dabigatran etexilate, and can be predicted by APTT and protein C activity to some extent.